Back HIV Treatment Approved HIV Drugs EACS 2013: GSK1265744 Rapidly Suppresses HIV, Appears Safe At Selected Dose

EACS 2013: GSK1265744 Rapidly Suppresses HIV, Appears Safe At Selected Dose


The experimental HIV integrase inhibitor GSK1265744 demonstrated rapid and potent antiviral activity and good tolerability for treatment-naive patients in the LATTE study, according to a report at the 14th European AIDS Conference this week in Brussels.

Integrase inhibitors are among the most well-tolerated antiretroviral medications. GSK1265744 (or GSK744 for short), being developed by GlaxoSmithKline, is similar to the recently approved dolutegravir. It is being tested both as a once-daily oral drug and as a long-acting injectable that may allow for once-monthly administration. A recently presented analysis of 8 studies showed that it is safe with no notable safety concerns.

David Margolis from GlaxoSmithKline and colleagues evaluated the safety, tolerability, and efficacy of GSK744 in previously untreated people with HIV.

The Phase 2b LATTE trial started with a 24-week induction phase comparing 3 oral doses of GSK744 plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) to inform selection of an optimal dose for further development. At week 24, participants with stable viral suppression discontinued NRTIs and switched to a simplified dual maintenance regimen of GSK744 plus oral rilpivirine (Edurant).

The primary endpoint of this partially-blinded, dose-ranging, multicenter studyis undetectable HIV viral load (<50 copies/mL) at 48 weeks. Margolis reported interim 24-week findings.

This analysis included 243 treatment-naive patients. Almost all were men; Margolis explained that the lack of women was in part due to a restriction on use of hormonal contraception, since drug interactions with GSK744 are not yet known. A majority of participants (about 60%) were white, about 30% were black, and the median age was about 34 years. The median CD4 T-cell count was approximately 410 cells/mm3 and 16% had high baseline viral load (>100,000 copies/mL). About 5% were coinfected with hepatitis C.

Participants were randomly assigned to receive GSK744 at doses of 10 mg, 30 mg or 60 mg, or 600 mg efavirenz, all once daily. They also started on 2 investigator-selected NRTIs, about 60% taking tenofovir/emtricitabine (Truvada) and 40% taking abacavir/lamivudine (Epzicom).


  • At 24 weeks, 87% of participants taking GSK744 achieved undetectable viral load (all dose arms combined), compared with 74% of those taking efavirenz in a snapshot analysis.
  • Response was similar with all GSK744 doses (88%, 85%, and 87%).
  • There was no significant difference according to NRTI backbone.
  • Viral load fell rapidly after starting treatment in all GSK744 dose groups; people taking GSK744 achieved viral suppression significantly sooner than those taking efavirenz, with 76% vs 24% having undetectable HIV RNA by week 4.
  • CD4 T-cell gains were similar for GSK744 and efavirenz recipients at week 24 (185 and 159 cells/mm3), though the increase was faster in the GSK744 arms (123 vs 59 cells/mm3 at week 8).
  • Virological failure rates in the snapshot analysis were 6% with GSK744 (all arms combined) and 15% with efavirenz.
  • Protocol-defined virological failure -- the narrower criteria used to determine who was eligible for the maintenance phase -- was uncommon, with 6 total cases: 1 in each GSK744 dose arm (2% combined) and 3 in the efavirenz arm (5%).
  • All these patients underwent genotypic or phenotypic resistance testing and no integrase, NRTI, or NNRTI mutations were detected.
  • People taking GSK744 were about half as likely to withdraw from the study as those taking efavirenz (12% vs 26%), with no notable differences across GSK744 dose groups; this was mainly driven by a significantly lower dropout rate due to adverse events among GSK744 recipients (2% vs 11%).
  • Overall rates of grade 2-4 adverse events were similar, 18% with GSK744 and 16% with efavirenz.
  • As expected, people taking efavirenz had more neuropsychiatric or central nervous system side-effects.
  • Headache, usually mild to moderate, was more common with GSK744 (<3% vs 0%).
  • 6 people taking GSK744 had serious adverse events (none considered drug-related), as did 3 people taking efavirenz (1 suicide attempt deemed drug-related).
  • Laboratory abnormalities occurred with similar frequency among GSK744 and efavirenz recipients overall.
  • However, abnormalities were more common with the highest GSK744 dose: one-quarter developed ALT liver enzyme elevations which were usually mild, but there were 2 transient grade 4 (severe) elevations in people with pre-existing liver disease; lipase elevation occurred in 8% in this arm, but there were no cases of pancreatitis.

"Oral [GSK744] administered once-daily with 2 NRTIs was associated with a good treatment response," the researchers concluded.

Based on these findings, the 30 mg GSK744 dose was selected. The maintenance phase of LATTE testing GSK744 plus rilpivirine maintenance therapy is currently underway. Results from that part of the trial will prepare the way for a Phase 2b study of combined long-acting injectable formulations of both drugs, which may one day be used as monthly maintenance therapy or pre-exposure prophylaxis (PrEP).



D Margolis, L Bhatti, G Smith, et al. Once-daily oral GSK1265744 (GSK744) as part of combination therapy in antiretroviral naive adults: 24-week safety and efficacy results from the LATTE study (LAI116482). 14th European AIDs Conference (EACS 2013). Brussels. October 16-19, 2013. Abstract PS7/1.